AU2001292138A1 - Quinazoline derivatives with anti-tumour activity - Google Patents
Quinazoline derivatives with anti-tumour activityInfo
- Publication number
- AU2001292138A1 AU2001292138A1 AU2001292138A AU9213801A AU2001292138A1 AU 2001292138 A1 AU2001292138 A1 AU 2001292138A1 AU 2001292138 A AU2001292138 A AU 2001292138A AU 9213801 A AU9213801 A AU 9213801A AU 2001292138 A1 AU2001292138 A1 AU 2001292138A1
- Authority
- AU
- Australia
- Prior art keywords
- quinazoline derivatives
- tumour activity
- tumour
- activity
- quinazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00402844 | 2000-10-13 | ||
| EP00402844.5 | 2000-10-13 | ||
| PCT/GB2001/004498 WO2002030924A1 (en) | 2000-10-13 | 2001-10-09 | Quinazoline derivatives with anti-tumour activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001292138A1 true AU2001292138A1 (en) | 2002-04-22 |
Family
ID=8173901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001292138A Abandoned AU2001292138A1 (en) | 2000-10-13 | 2001-10-09 | Quinazoline derivatives with anti-tumour activity |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6849625B2 (en) |
| EP (1) | EP1326859A1 (en) |
| JP (1) | JP2004511479A (en) |
| AU (1) | AU2001292138A1 (en) |
| WO (1) | WO2002030924A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03001332A (en) | 2000-08-21 | 2004-07-08 | Astrazeneca Ab | Quinazoline derivatives. |
| WO2002030926A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives |
| DE60144284D1 (en) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | NITROGENIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
| ATE409185T1 (en) | 2001-04-19 | 2008-10-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES |
| CA2447139C (en) * | 2001-05-11 | 2013-11-19 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| JP4326328B2 (en) | 2001-07-16 | 2009-09-02 | アストラゼネカ アクチボラグ | Quinoline derivatives and their use as tyrosine kinase inhibitors |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| AU2003278383B2 (en) | 2002-11-04 | 2007-06-14 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| ES2305844T3 (en) | 2003-09-16 | 2008-11-01 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE. |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| PL2392565T3 (en) | 2003-09-26 | 2014-08-29 | Exelixis Inc | c-Met modulators and methods of use |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CA2553433A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer |
| EA011402B1 (en) | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Nitrogen-containing heterocyclic compounds and pharmaceutical use thereof |
| ES2315834T3 (en) | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINA. |
| CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
| EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
| US7998949B2 (en) | 2007-02-06 | 2011-08-16 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| MX2009009782A (en) * | 2007-03-15 | 2010-09-10 | Ludwig Inst Cancer Res | Treatment method using egfr antibodies and src inhibitors and related formulations. |
| EP2220078B1 (en) * | 2007-10-29 | 2013-05-22 | Amgen, Inc | Benzomorpholine derivatives and methods of use |
| BRPI0907916A2 (en) | 2008-02-07 | 2015-07-28 | Boehringer Ingelheim Int | Spirocycle heterocycles, medicaments containing such compounds, and processes for preparing them |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| WO2009138781A1 (en) | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline |
| US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| TW201920110A (en) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | Containing N-(4-{[6,7-bis(methoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-di Pharmaceutical composition of methotrexate malate and use thereof |
| UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
| CN103819343B (en) * | 2014-02-17 | 2016-03-23 | 青岛农业大学 | The preparation method of the fluoro-6-nitrophenols of compound 2-allyl group-4-and agricultural biological activity |
| EP3194572B1 (en) | 2014-07-30 | 2023-10-25 | Yeda Research and Development Co. Ltd. | Media for culturing pluripotent stem cells |
| CN109019536A (en) * | 2018-08-27 | 2018-12-18 | 陕西师范大学 | A method of preparing nano aluminum nitride powder |
| WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US173646A (en) * | 1876-02-15 | Improvement in cotton openers and cleaners | ||
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE69222637T2 (en) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | UP TO MONO AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH INHIBITING EFFECT ON EGF AND / OR PDGF RECEPTOR TYROSINKINASE |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| AU686843B2 (en) | 1994-02-23 | 1998-02-12 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| TW321649B (en) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| PT912559E (en) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| AR012634A1 (en) | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| TR200500745T2 (en) | 1999-02-10 | 2005-05-23 | Astrazeneca Ab | Quinazoline derivatives as inhibitors of vascular development. |
| CN1391561A (en) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | Quinazoline compounds and pharmaceutical compositions containing them |
| CA2403365A1 (en) | 2000-04-07 | 2001-10-18 | Astrazeneca Ab | Quinazoline compounds |
| UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
| MXPA03001332A (en) | 2000-08-21 | 2004-07-08 | Astrazeneca Ab | Quinazoline derivatives. |
| WO2002030926A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives |
| EP1332141A1 (en) | 2000-10-25 | 2003-08-06 | AstraZeneca AB | Quinazoline derivatives |
| ATE409185T1 (en) | 2001-04-19 | 2008-10-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES |
| WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| JP4326328B2 (en) | 2001-07-16 | 2009-09-02 | アストラゼネカ アクチボラグ | Quinoline derivatives and their use as tyrosine kinase inhibitors |
| WO2003047584A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
| AU2002347336A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
-
2001
- 2001-10-09 US US10/398,793 patent/US6849625B2/en not_active Expired - Fee Related
- 2001-10-09 JP JP2002534310A patent/JP2004511479A/en active Pending
- 2001-10-09 EP EP01972364A patent/EP1326859A1/en not_active Withdrawn
- 2001-10-09 AU AU2001292138A patent/AU2001292138A1/en not_active Abandoned
- 2001-10-09 WO PCT/GB2001/004498 patent/WO2002030924A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US6849625B2 (en) | 2005-02-01 |
| EP1326859A1 (en) | 2003-07-16 |
| WO2002030924A1 (en) | 2002-04-18 |
| WO2002030924A9 (en) | 2003-05-22 |
| JP2004511479A (en) | 2004-04-15 |
| US20040048881A1 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001292138A1 (en) | Quinazoline derivatives with anti-tumour activity | |
| AU2002221047A1 (en) | Quinazolinone derivatives | |
| AU7860901A (en) | Quinazoline derivatives | |
| AU2002212436A1 (en) | Quinazoline derivatives | |
| AU2960599A (en) | Quinazoline derivatives | |
| SI1676845T1 (en) | New quinazoline derivatives | |
| AU2001226384A1 (en) | Bed construction with reduced sagging | |
| AU2002236653A1 (en) | Bed construction with reduced sagging | |
| AU2002359767A1 (en) | Absorbent article with stabilized absorbent structure | |
| AUPR975601A0 (en) | Quinazolinone derivatives | |
| AU2002218029A1 (en) | Modified factor viia | |
| AU5826100A (en) | Benzazepinones and quinazolines | |
| AU2002359805A1 (en) | Absorbent article with stabilized absorbent structure | |
| AU2002352444A1 (en) | Quinazolinedione derivatives | |
| AU7419300A (en) | Quinazolinones | |
| AU2001292137A1 (en) | Quinazoline derivatives | |
| AU5391099A (en) | Substituted quinazoline derivatives | |
| AU1135701A (en) | Compositions with anti-prostate cancer activity | |
| AU7654800A (en) | Quinazolinones | |
| AU2000265871A1 (en) | Roof with exposed openings | |
| AU2001263850A1 (en) | Pyrimidine-sulfonamides having endothelin-antagonist activity | |
| AU2002216758A1 (en) | Quinazolines with therapeutic use | |
| AU2001239311A1 (en) | Novel imidazole derivatives with anti-inflammatory activity | |
| AU2001240150A1 (en) | Quinazoline synthesis | |
| AU2002358160A1 (en) | Benzocyclodecane derivatives with antitumor activity |